Roy Herbst elected to Friends board of directors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Roy S. Herbst, deputy director of Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at Yale School of Medicine, was elected to the Friends of Cancer Research Board of Directors.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


To improve evidence generation in studies designed to bring therapeutic agents to market, FDA is urging drug sponsors not to skip dose optimization at the outset of clinical development. The agency is also telling industry that it’s open to accepting trials that have pragmatic elements and are augmented by data generated in academia.